Human Nuclease-sensitive element-binding protein 1(YBX1) ELISA kit

Code CSB-EL026247HU
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
Y box binding protein 1
Alternative Names
BP 8 ELISA Kit; CBF-A ELISA Kit; CCAAT binding transcription factor I subunit A ELISA Kit; CCAAT-binding transcription factor I subunit A ELISA Kit; CSDA2 ELISA Kit; CSDB ELISA Kit; DBPB ELISA Kit; DNA binding protein B ELISA Kit; DNA-binding protein B ELISA Kit; EFI-A ELISA Kit; Enhancer factor I subunit A ELISA Kit; MDR NF1 ELISA Kit; MGC104858 ELISA Kit; MGC110976 ELISA Kit; MGC117250 ELISA Kit; NSEP 1 ELISA Kit; NSEP1 ELISA Kit; Nuclease sensitive element binding protein 1 ELISA Kit; Nuclease-sensitive element-binding protein 1 ELISA Kit; p50 ELISA Kit; Q15905 ELISA Kit; Y-box binding protein 1 ELISA Kit; Y-box transcription factor ELISA Kit; Y-box-binding protein 1 ELISA Kit; YB 1 ELISA Kit; YB-1 ELISA Kit; YBOX1_HUMAN ELISA Kit; YBX 1 ELISA Kit; ybx1 ELISA Kit
Abbreviation
YBX1
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates, cell lysates
Detection Range
31.25 pg/mL-2000 pg/mL
Sensitivity
7.8 pg/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Epigenetics and Nuclear Signaling
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human YBX1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)
1:1 Average % 89
Range % 81-93
1:2 Average % 102
Range % 95-109
1:4 Average % 95
Range % 91-99
1:8 Average % 86
Range % 83-91
Recovery
The recovery of human YBX1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range
Serum (n=5) 104 101-109
EDTA plasma (n=4) 97 93-100
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/ml OD1 OD2 Average Corrected
2000 2.658 2.698 2.678 2.575
1000 2.381 2.451 2.416 2.313
500 1.974 1.962 1.968 1.865
250 1.229 1.169 1.199 1.096
125 0.698 0.687 0.693 0.590
62.5 0.400 0.412 0.406 0.303
31.25 0.209 0.211 0.210 0.107
0 0.101 0.105 0.103  
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

This Human YBX1 ELISA Kit was designed for the quantitative measurement of Human YBX1 protein in serum, plasma, tissue homogenates, cell lysates. It is a Sandwich ELISA kit, its detection range is 31.25 pg/mL-2000 pg/mL and the sensitivity is 7.8 pg/mL.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
DNA- and RNA-binding protein involved in various processes, such as translational repression, RNA stabilization, mRNA splicing, DNA repair and transcription regulation. Predominantly acts as a RNA-binding protein: binds preferentially to the 5'-[CU]CUGCG-3' RNA motif and specifically recognizes mRNA transcripts modified by C5-methylcytosine (m5C). Promotes mRNA stabilization: acts by binding to m5C-containing mRNAs and recruiting the mRNA stability maintainer ELAVL1, thereby preventing mRNA decay. Component of the CRD-mediated complex that promotes MYC mRNA stability. Contributes to the regulation of translation by modulating the interaction between the mRNA and eukaryotic initiation factors. Plays a key role in RNA composition of extracellular exosomes by defining the sorting of small non-coding RNAs, such as tRNAs, Y RNAs, Vault RNAs and miRNAs. Probably sorts RNAs in exosomes by recognizing and binding C5-methylcytosine (m5C)-containing RNAs. Acts as a key effector of epidermal progenitors by preventing epidermal progenitor senescence: acts by regulating the translation of a senescence-associated subset of cytokine mRNAs, possibly by binding to m5C-containing mRNAs. Also involved in pre-mRNA alternative splicing regulation: binds to splice sites in pre-mRNA and regulates splice site selection. Also able to bind DNA: regulates transcription of the multidrug resistance gene MDR1 is enhanced in presence of the APEX1 acetylated form at 'Lys-6' and 'Lys-7'. Binds to promoters that contain a Y-box (5'-CTGATTGGCCAA-3'), such as MDR1 and HLA class II genes. Promotes separation of DNA strands that contain mismatches or are modified by cisplatin. Has endonucleolytic activity and can introduce nicks or breaks into double-stranded DNA, suggesting a role in DNA repair. The secreted form acts as an extracellular mitogen and stimulates cell migration and proliferation.
Gene References into Functions
  1. The study establishes YBX1 as a posttranscriptional effector required for maintenance of epidermal homeostasis. PMID: 29712925
  2. Phosphorylation of nuclear YB-1 after stimulation with epidermal growth factor is associated with nuclear accumulation of p90 ribosomal S6 kinase but not of YB-1. PMID: 30126195
  3. this study identifies a novel lncRNA termed lncRNA-AWPPH which is highly expressed in hepatocellular carcinoma (HCC), indicates poor prognosis of HCC patients, and promotes HCC cell proliferation, migration, and in vivo tumor growth and metastasis via a novel regulatory mechanism of interacting with YBX1. PMID: 28428004
  4. YB-1 regulates miR-155 expression via c-Myb in the laryngeal squamous cell carcinoma.Laryngeal squamous cell carcinoma patients with high YB-1 expression showed poor overall survival. PMID: 29517281
  5. infiltrating CD4 + T cells promoted TGFbeta1 expression in both renal cell carcinoma and T cells and regulated renal cell carcinoma cells proliferation via modulating TGFbeta1/YBX1/ HIF2alpha signals PMID: 29289594
  6. structural basis of the interactions between YB-1 and mRNAs carrying the aforementioned motifs PMID: 29133115
  7. YB-1 silencing sensitized SH-SY5Y cells to cisplatin and promoted the apoptosis induced by cisplatin due to down-regulation of multidrug resistance (MDR) 1 protein via NF-kappaB signaling pathway. PMID: 28382490
  8. These results suggest that extracellular vesicles and exosomes could play a role in the purging and intercellular transfer of excess free RNAs, including full-length transfer RNAs and other small noncoding RNAs. PMID: 29073095
  9. YB-1 promoted lung adenocarcinoma growth and progression in vitro and in vivo through directly binding to the MACC1 promoter and enhancing MACC1/c-Met pathway. PMID: 28624808
  10. Data indicate that YB-1 translocates to the nucleus coordinately with p53 expression and is involved in gemcitabine resistance in bladder cancer suggesting that nuclear expression of YB-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer. PMID: 28714514
  11. Results show that YBX1 expression is regulated by TP53TG1 which binds to YBX1 promoter and prevents its nuclear localization. PMID: 27821766
  12. Kindlin-2 is up-regulated in glioma cells and acts as an oncogene. It is an independent risk factor for poor prognosis. The Kindlin-2/YB-1/beta-catenin complex promotes EGFR transcription and contributes to glioma progression. Kindlin-2 is a potential diagnostic and prognostic marker in glioma, and inhibition of Kindlin-2 may be a novel strategy for glioma treatment. PMID: 27713156
  13. Results showed that YB-1 promoted hepatocellular carcinoma (HCC) cell proliferation, migration and colony formation. Also, YB-1 was found to increased drug resistance in HCC. These findings suggested that YB-1 was a key factor in HCC tumorigenesis and maintained the HCC initiating cell population. PMID: 27911878
  14. Furthermore, use of both indirubin 3'-oxime and actinomycin D in combination increased the anticancer effect on HepG2 cells. Indirubin 3'-oxime is a novel and efficient inhibitor of anticancer agent-induced YB-1 nuclear translocation. PMID: 29274785
  15. It would appear that YB-1 could regulate cell invasion and migration via downregulation of its indirect target coronin-1C. The association between YB-1 and coronin-1C offers a novel approach by which metastasis of breast cancer cells could be targeted and abrogated. PMID: 28302118
  16. Inhibition of YBX1 suppressed lung cancer growth partly via the CDC25a pathway and high expression of YBX1/CDC25a predicts poor prognosis in human lung adenocarcinoma. PMID: 27384875
  17. The long noncoding RNA CAR intergenic 10 bound and stabilized transcription factor Y-box-binding protein 1 (YB-1), leading to up-regulation of the epidermal growth factor receptor (EGFR) and proliferation of lung cancer cells. PMID: 27322209
  18. Results firstly reported that YB-1 whose mRNA expression is regulated by HPV18 E6 promotes epithelial-mesenchymal transition and progression of cervical cancer via enhancing the expressions of Snail. PMID: 28708785
  19. YB-1 localization was significantly altered in the nuclei of tumor blasts derived from bone marrow or peripheral blood. PMID: 28009354
  20. Two interacting partners of urokinase-type plasminogen activator (uPA) receptor, the cysteine-rich angiogenic inducer 61 (Cyr61) and the Y-box-binding protein 1 (YB-1) were identified and their differential expression demonstrated in the triple-negative breast cancer (TNBC) cells as well as in tumors. PMID: 27286449
  21. No other significant associations between clinical prognostic factors and YB-1/p18 serum levels were detected. PMID: 27371774
  22. Data suggest that oncogenic Y-box binding protein 1 (YB-1) indirectly enhances transforming growth factor beta (TGFbeta) signaling cascades via Sma/Mad related protein 2 (Smad2)phospho-activation and may represent a promising factor for future diagnosis and therapy of breast cancer. PMID: 29187452
  23. High YBX1 expression is associated with invasion in nasopharyngeal carcinoma. PMID: 29024700
  24. TCTP interacted with Y-box-binding protein 1 (YBX1), and their interaction was localized to the N-terminal region of TCTP and the 1-129 amino acid (aa) residues of YBX1. The interaction of TCTP with YBX1 might cooperate or coordinate their functions in the control of diverse regulatory pathways in cancer cells. PMID: 27607350
  25. YB-1 expression promotes pancreatic cancer metastasis that is inhibited by microRNA-216a. PMID: 28782557
  26. findings point to YB-1 and NSUN2 as possible mediators of the process of transfer of specific mRNAs into exosomes, allowing us to speculate on an involvement of these proteins in the mRNA sorting via the recognition of the above motifs PMID: 28341602
  27. YB-1 is induced by Shh in CGNPs PMID: 26725322
  28. FOXO3a nuclear expression was inversely correlated with YB-1 nuclear expression in prostate cancer tissues. PMID: 27699813
  29. these findings define a mechanism of drug resistance through which YBX1 contributes to antiestrogen bypass in breast cancer cells PMID: 27879270
  30. High YB1 expression is associated with Cisplatin Resistance in Gastric Cancer. PMID: 27013200
  31. Collectively, these findings demonstrate a novel role of YBX1 in maintaining the stemness of CSCs and metastasis, unveiling YBX1 as promising therapeutic target for NSCLC treatments. PMID: 28400280
  32. These studies reveal the functional role of YB-1 in the Angiogenin-mediated stress response program. PMID: 27174937
  33. Together, these results indicate that transportin-1 mediates YB-1 nuclear translocation. PMID: 27794479
  34. YB-1 is a novel binding factor for hypoxia-responsive elements that participates in fine-tuning of the hypoxia transcriptome. PMID: 27524241
  35. The long noncoding RNA highly up-regulated in liver cancer (HULC) promotes the phosphorylation of YB-1 through the extracellular signal-regulated kinase pathway, in turn regulates the interaction of YB-1 with certain oncogenic mRNAs, and consequently accelerates the translation of these mRNAs in the process of tumorigenesis. PMID: 28027578
  36. glycosylated-YB-1 mainly enhanced cell proliferation through congenerous actions with YB-1 phosphorylation and thus played indispensable roles in fine-tuning cell proliferation PMID: 27751836
  37. Silencing of YB-1 could sensitize DLBCL cells to mitoxantrone and overcome cell adhesion-mediated drug resistance (CAM-DR) phenotype in an AKT-dependent manner. PMID: 27397581
  38. these data suggest that C1QBP could regulate YBX1 to suppress the AR-enhanced RCC cell invasion. Targeting this newly identified C1QBP/YBX1/AR/MMP9 signal pathway may provide a new potential therapy to better suppress RCC metastasis. PMID: 28107702
  39. Tumor growth and liver metastasis formation were significantly suppressed in nude mice after implantation of YB-1-silenced PDAC cells, and the YB-1 targeting antisense oligonucleotide significantly inhibited the growth of subcutaneous tumors. PMID: 26939718
  40. we propose a model whereby high YB-1 levels in some TNBC cells can lead to reduced levels of EGR1, which in turn promotes slow cell cycling and resistance to PTX. Therefore YB-1 and EGR1 levels are biologically linked and may provide a biomarker for TNBC response to PTX. PMID: 27072400
  41. LL37 induced YB1 expression, and increased tumor cell proliferation, migration and invasion of A375 and A875 malignant melanoma cell lines. PMID: 27922666
  42. Down-regulation of miR-137 conferred OXA resistance in parental cells, while over-expression of miR-137 sensitized resistant cells to OXA, which was partly rescued by YBX1 siRNA. PMID: 28035913
  43. suggests that selective inhibition of translation of YB-1 mRNA, and probably some other mRNAs as well, by mTOR kinase inhibitors is not mediated by the action of the 4E-binding protein upon functions of the 4F-group translation initiation factors PMID: 26931209
  44. Cytoplasmic expression of YB-1 was associated with more aggressive tumor and poor overall survival in breast cancer. PMID: 26193840
  45. High-grade nuclear YB-1 expression was detected in 62.9% of colorectal cancer cases and was found to be an independent predictor of poorer overall survival and relapse-free survival. PMID: 27354655
  46. Study shows that DeltaNp63alpha controls YB-1 protein stability suggesting that DeltaNp63alpha/YB-1 cross talk is relevant for survival of basal keratinocytes in stratified epithelia. PMID: 27168020
  47. These findings demonstrate the oncogenic roles of YB-1 in esophageal squamous cell carcinoma (ESCC) and support it as a target for ESCC therapy. PMID: 27044807
  48. Immunofluorescence staining was used to detect the levels of YB-1 in the cytoplasm and the nucleus, and results indicated that the intracellular distribution was significantly associated with the pathological grade of glioma PMID: 26936129
  49. Results show that high GOLPH3 and nuclear/cytoplasmic YB-1 expression correlated with a poor prognosis in patients with prostate cancer. PMID: 26794392
  50. Data suggest that poly(ADP-ribosyl)ation of YB-1 (multifunctional Y-box binding protein 1) is catalyzed by PARP1 [poly(ADP-ribose)polymerase 1] and can be up-regulated by damaged DNA. PMID: 26453809

Show More

Hide All

Subcellular Location
Cytoplasm. Nucleus. Cytoplasmic granule. Secreted. Secreted, extracellular exosome.
Database Links

HGNC: 8014

OMIM: 154030

KEGG: hsa:4904

STRING: 9606.ENSP00000361626

UniGene: Hs.473583

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X